You are here

Ethical guidelines for the research and innovation of psychedelic assisted therapies: A scoping review

Description 
There has been an explosion in research on psychedelic drugs in recent years, including clinical trials of psilocybin and MDMA (ecstasy) for the treatment of a range of mental and neurological disorders (e.g. depression, anxiety, addiction, PTSD, autism and Alzheimer's). Despite this surge in research, there has been surprising little examination of the unique ethical issues that studies involving the consumption of psychedelic drugs. These include: obtaining informed consent to an experience that is difficult to communicate and understand, the use of therapeutic touch by trial therapists while in a state of disordered consciousness, equitable access to research trials and treatment, diverse representation within research teams and study participants, post trial care, and just recognition, respect and reparation in the use of Indigenous knowledge. This project will conduct a scoping review to identify ethical issues and guidance discussed in the literature, highlighting areas requiring greater consideration. The aim of the project will be to develop a set of ethical guidelines for the responsible research and innovation of psychedelic therapies.
Essential criteria: 
Minimum entry requirements can be found here: https://www.monash.edu/admissions/entry-requirements/minimum
Keywords 
psychedelics, ethics, scoping review, responsible research and innovation, RRI
School 
School of Psychological Sciences » The Turner Institute for Brain and Mental Health
Available options 
Masters by research
Masters by coursework
Honours
BMedSc(Hons)
Time commitment 
Full-time
Part-time
Physical location 
Monash Biological Imaging facility
Co-supervisors 
Assoc Prof 
Adrian Carter
Dr 
John Gardner

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.